ODN 1826

ODN 1826

Oligodeoxyribonucleotides containing CpG motifs (CpG ODNs) are widely used for activation of immune cells, such as human PBMCs, murine splenocytes or isolated immune cells, e.g., B cells and pDCs. They also activate signalling in TLR9-expressing recombinant cell lines.
ODN 1826 strongly activates murine TLR9. It is a B-class ODN for activation of B cells, induction of Il-6 secretion, and activation of NF-kB-signalling pathways.

Background information

TLR9 is a prominent member of the toll-like-receptor (TLR) family recognizing pathogen-associated molecular patterns. TLR9 recognizes specifically unmethylated CpG motifs in bacterial DNA leading to activation of immune cells
1
,
2
. These effects can be mimicked by short synthetical oligodeoxyribonucleotides (ODNs) containing unmethylated CpG motifs
3
.
Several classes of CpG ODN have been identified and can be distinguished by their effects on certain cell types. A-class ODNs containing 5’ and 3’ G-rich stretches induce high levels of type I IFN but show low activation of B cell proliferation. B-class ODNs activate B cells and TLR9-dependent NFkB signalling in recombinant cell lines but show low induction of IFN-α. C-class ODN induce high amounts of IFN-α and activate B cells. The recently discovered new P-Class ODNs show similar but superior properties to C-class ODNs.
ODN 1826 is a B-class ODN that strongly activates murine TLR9.

Applications

B-class ODN for activation of B cells , induction of Il-6 secretion, and activation of NF-kB-signalling pathways.
Murine B-Class ODN 1826 can be used as an adjuvant for vaccination strategies.
4,5
  • Selected References

    1. Hemmi, H. et al. (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745
    2. Krieg, A. M. et al. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549
    3. Bauer, S. et al. (2001) Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. U.S.A. 98: 9237-9242
    4. Klinman, D. M. (2006) Adjuvant activity of CpG oligodeoxynucleotides. Int. Rev. Immunol. 25: 135-154
    5. Kumar, S. et al. (2004) CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect. Immun. 72: 949-957
Product options: 2

Product information

Size
Order no.
Price

ODN 1826

  • For research use only
200 µg
130-100-274
-

ODN 1826

  • For research use only
1 mg
130-100-103
-